Imagine a world where woolly mammoths roam the tundra once more—not in a prehistoric dream but as a living, breathing reality. This isn’t science fiction; it’s cutting-edge science happening ...

A startup company is trying to raise money to bring back the woolly mammoth. Colossal Biosciences Inc. uses DNA and genomics in hopes of re-introducing extinct animals to the modern-day world.

Instead of dinosaurs, Colossal has set its sights on more recently lost species including the dodo, the thylacine — also known as the Tasmanian tiger– and the woolly mammoth. The last ...

Among its first rewilding goals: bringing back the woolly mammoth. The last, isolated mammoth populations died out 4,000 years ago, with their extinction blamed on hunting by humans and climate ...

Woolly mammoths went extinct around 4,000 years ago, but scientists claim America will soon see the prehistoric animal in 2028. Colossal Biosciences, a Texas-based biotechnology and genetic ...

Colossal has also altered the DNA sequence in chicken primordial germ cells (PGCs), injected them into embryos, and successfully hatched chimeric chicks. Their offspring will be surrogates for dodos.

Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation ...

Digital rendering of the long-extinct woolly mammoth. Courtesy Colossal Biosciences The woolly mammoth could be brought back from extinction in just three years’ time—that is, if everything ...

(Bloomberg) -- A biotechnology startup working to bring back animals from extinction has raised $200 million at a valuation of $10.2 billion, more than six times its valuation just two years ago.

Learn More Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth. Dallas- and Boston-based Colossal is making strides in the ...

No, this isn’t a new Jurassic Park plot: A real-life woolly mammoth could be on Earth by the decade’s end. Biotechnology start-up Colossal Biosciences Inc., which is using DNA and genomics in ...